Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions

Glioblastoma multiforme (GBM) is an aggressive intracranial tumor characterized by local and distant brain relapse despite aggressive therapy. Current standard treatment includes surgical resection followed by radiation with concurrent and adjuvant temozolomide as part of a combined modality approac...

Full description

Saved in:
Bibliographic Details
Published inSeminars in radiation oncology Vol. 26; no. 4; pp. 281 - 298
Main Authors Corso, Christopher D., Bindra, Ranjit S.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.10.2016
Subjects
Brain Neoplasms - therapy
Combined Modality Therapy - methods
Combined Modality Therapy - trends
Glioblastoma - therapy
Hematology, Oncology and Palliative Medicine
Humans
Immunotherapy
Medical Oncology
Radiation-Sensitizing Agents - therapeutic use
Radiology
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Glioblastoma multiforme (GBM) is an aggressive intracranial tumor characterized by local and distant brain relapse despite aggressive therapy. Current standard treatment includes surgical resection followed by radiation with concurrent and adjuvant temozolomide as part of a combined modality approach. In this review, the historical basis for the current standard treatment is discussed as well as other recent combined modality successes and failures. An overview of emerging combined modality therapies for GBM is presented including immunotherapy, and rationally designed radiosensitizers. Unanswered questions facing the oncology community regarding the treatment of GBM are also discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1053-4296
1532-9461
DOI:10.1016/j.semradonc.2016.06.003